Sanofi: new positive data for PD-1 Libtayo

(CercleFinance.com) - Sanofi announced on Friday that new long-term data from a pivotal Phase II trial of the PD-1 inhibitor Libtayo in advanced cutaneous squamous cell carcinoma (SCC) has been presented today.


"These results demonstrate both longer durability and higher complete response (CR) rates than previously reported. Furthermore, the data make up part of the largest and most mature prospective clinical dataset in patients with metastatic CSCC (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or radiation," the group said.

The data were presented during the virtual 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.


Copyright (c) 2020 CercleFinance.com. All rights reserved.